Format

Send to

Choose Destination
See comment in PubMed Commons below
Br J Psychiatry. 2002 Oct;181:315-20.

Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder.

Author information

1
Novartis Pharmaceuticals, Basel, Switzerland.

Abstract

BACKGROUND:

Little is known about the effect of pharmacotherapy in the prevention of post-traumatic stress disorder (PTSD) relapse.

AIMS:

To assess the efficacy and tolerability of fluoxetine in preventing PTSD relapse.

METHOD:

This was a double-blind, randomised, placebo-controlled study. Following 12 weeks of acute treatment, patients who responded were rerandomised and continued in a 24-week relapse prevention phase with fluoxetine (n=69) or placebo (n=62). The primary efficacy assessment was the prevention of PTSD relapse, based on the time to relapse.

RESULTS:

Patients in the fluoxetine/fluoxetine group were less likely to relapse than patients in the fluoxetine/placebo group (P=0.027). There were no clinically significant differences in treatment-emergent adverse events between treatment groups.

CONCLUSIONS:

Fluoxetine is effective and well tolerated in the prevention of PTSD relapse for up to 6 months.

PMID:
12356658
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center